IPHA
Innate PharmaIPHA
IPHA
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
13% more funds holding
Funds holding: 8 [Q3] → 9 (+1) [Q4]
0.13% less ownership
Funds ownership: 0.29% [Q3] → 0.17% (-0.13%) [Q4]
53% less capital invested
Capital invested by funds: $545K [Q3] → $255K (-$290K) [Q4]
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$11.50
502%
upside
Avg. target
$11.50
502%
upside
High target
$11.50
502%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth 22% 1-year accuracy 45 / 203 met price target | 502%upside $11.50 | Buy Reiterated | 28 Mar 2025 |
Financial journalist opinion
Based on 6 articles about IPHA published over the past 30 days
Neutral
Seeking Alpha
4 days ago
Innate Pharma S.A. (IPHA) Q4 2024 Earnings Call Transcript
Innate Pharma S.A. (NASDAQ:IPHA ) Q4 2024 Earnings Conference Call March 27, 2025 9:00 AM ET Company Participants Henry Wheeler - VP, IR and Communications Jonathan Dickinson - CEO Yannis Morel - COO Sonia Quaratino - CMO Frederic Lombard - CFO Conference Call Participants Daina Graybosch - Leerink Partners Swayampakula Ramakanth - H.C.
Neutral
Business Wire
5 days ago
Innate Pharma Reports Full Year 2024 Financial Results and Business Update
MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the year ending December 31, 2024. The consolidated financial statements are attached to this press release. “Our strategy is clear: drive innovation through our ANKET® NK-cell engager platform and accelerate our ADC programs. We are making strong clinical progress, with our lead proprietary ANKET®, IPH6501 ad.
Neutral
Business Wire
6 days ago
Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting
MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30 in Chicago, Illinois. In addition, Jonathan Dickinson, CEO of Innate Parma, will present.
Neutral
Business Wire
1 week ago
Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference.
Positive
Seeking Alpha
1 week ago
Innate Pharma: Moving Into The Padcev Space
Innate Pharma's diverse pipeline, including lacutamab, IPH6501, and IPH4502, shows promising clinical activity and potential for significant milestones in 2025. Lacutamab, a key asset, received US FDA Breakthrough Therapy designation, enhancing its development prospects and partnership potential. Financially, IPHA has a cash runway until the end of 2025, but may face a cash crunch, likely requiring equity raises or partnerships, in my opinion.
Neutral
Business Wire
1 week ago
Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for full year 2024 financial results.
Neutral
Business Wire
1 month ago
Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to participate in The 2025 Leerink Partners Global Healthcare Conference.
Positive
Seeking Alpha
1 month ago
Innate: Lacutamab Treatment Program Moves Forward With Potential Expansion
Positive results achieved in the open-label phase 2 TELLOMAK study, using lacutamab for the treatment of patients with relapsed/refractory Sezary Syndrome; Patients achieved a confirmed Objective Response Rate of 37.5%. Release of data from phase 2 study, using lacutamab for the treatment of patients with Peripheral T-cell Lymphoma, expected in 2025. Company actively seeking to establish a collaboration agreement with a pharmaceutical company to initiate a phase 3 study using lacutamab to target patients with Cutaneous T-Cell Lymphoma.
Neutral
Business Wire
1 month ago
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces U.S. FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary Syndrome.
Neutral
Business Wire
2 months ago
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the first patient was dosed in its Phase 1 study (NCT06781983), investigating the safety and tolerability of IPH4502, an innovative Antibody-Drug Conjugate (ADC), in patients with advanced solid tumors known to express Nectin-4. IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesi.
Charts implemented using Lightweight Charts™